Desirè Viola Trupia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Desirè Viola Trupia has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Costanza Volpi
Department of Advanced Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
4 shared publications Alessia Bertolotti
Department of Diagnostic Innovation Pathology Unit 2, Molecular Diagnostic and Research Fondazione IRCCS Istituto Nazionale Dei Tumori Milan Milan Italy
3 shared publications- Annunziata Gloghini
Department of Advanced Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
3 shared publications Chiara Costanza Volpi
Department of Diagnostic Innovation Pathology Unit 2, Molecular Diagnostic and Research Fondazione IRCCS Istituto Nazionale Dei Tumori Milan Milan Italy
3 shared publications- Giancarlo Pruneri
Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
3 shared publications - Daniele Lorenzini
Department of Diagnostic Innovation, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
2 shared publications
Latest Publications
- Open Access
Precision Immunopathology in Classic Hodgkin Lymphoma: From Conventional Pathology to Integrated Biologic Profiling
Classic Hodgkin lymphoma (cHL) is histologically defined by rare Hodgkin and Reed–Sternberg (HRS) cells embedded within an extensive, biologically active immune microenvironment that HRS cells actively recruit and reprogram to sustain their own survival. For decades, diagnosis has relied on morphology and a limited immunohistochemical panel (CD30, CD15, PAX5, CD20, EBER), an approach that confirms disease identity but provides little insight into the immune ecosystem that governs prognosis and treatment response. Over the past fifteen years, discovery of near-universal 9p24.1/CD274-PDCD1LG2-JAK2 copy-number alterations, CIITA gene fusions, B2M mutations, and NF-κB/JAK-STAT pathway activation has progressively reframed cHL—conceptually rather than through a formal reclassification—as a genetically driven disorder of immune evasion. In parallel, multiplex immunohistochemistry, imaging mass cytometry, digital spatial profiling, spatial transcriptomics, single-cell sequencing, whole-slide digital pathology, and machine-learning algorithms now allow the tumor-immune ecosystem to be mapped at unprecedented resolution. This convergence is giving rise to what we term “precision immunopathology”: an overarching conceptual framework, rather than a formal diagnostic category, that combines morphology with immune, molecular, spatial, and computational data and that, once prospectively validated, may refine prognostic stratification, prediction of benefit from PD-1 blockade and other immunotherapies, and non-invasive disease monitoring through circulating tumor DNA. At present, beyond the standard diagnostic panel, no tissue biomarker is required to select patients for PD-1 blockade or CD30-directed therapy. This review summarizes the evolution from conventional to precision immunopathology in cHL, discusses the technologies enabling this transition, grades each candidate biomarker and assay by level of evidence and clinical readiness (routine, clinically validated but non-routine, or investigational), incorporates the move of PD-1 blockade into first-line therapy (SWOG S1826) and the BrECADD regimen (HD21), proposes a minimum dataset for an integrated precision immunopathology report, and discusses the practical barriers—tissue availability, cost, turnaround time, standardization, and regulatory validation—that must be overcome before an ecosystem-centered diagnostic model can be translated into routine hematopathology practice.
Open AccessPrecision Immunopathology in Classic Hodgkin Lymphoma: From Conventional Pathology to Integrated Biologic Profiling
Classic Hodgkin lymphoma (cHL) is histologically defined by rare Hodgkin and Reed–Sternberg (HRS) cells embedded within an extensive, biologically active immune microenvironment that HRS cells actively recruit and reprogram to sustain their own survival. For decades, diagnosis has relied on morphology and a limited immunohistochemical panel (CD30, CD15, PAX5, CD20, EBER), an approach that confirms disease identity but provides little insight into the immune ecosystem that governs prognosis and treatment response. Over the past fifteen years, discovery of near-universal 9p24.1/CD274-PDCD1LG2-JAK2 copy-number alterations, CIITA gene fusions, B2M mutations, and NF-κB/JAK-STAT pathway activation has progressively reframed cHL—conceptually rather than through a formal reclassification—as a genetically driven disorder of immune evasion. In parallel, multiplex immunohistochemistry, imaging mass cytometry, digital spatial profiling, spatial transcriptomics, single-cell sequencing, whole-slide digital pathology, and machine-learning algorithms now allow the tumor-immune ecosystem to be mapped at unprecedented resolution. This convergence is giving rise to what we term “precision immunopathology”: an overarching conceptual framework, rather than a formal diagnostic category, that combines morphology with immune, molecular, spatial, and computational data and that, once prospectively validated, may refine prognostic stratification, prediction of benefit from PD-1 blockade and other immunotherapies, and non-invasive disease monitoring through circulating tumor DNA. At present, beyond the standard diagnostic panel, no tissue biomarker is required to select patients for PD-1 blockade or CD30-directed therapy. This review summarizes the evolution from conventional to precision immunopathology in cHL, discusses the technologies enabling this transition, grades each candidate biomarker and assay by level of evidence and clinical readiness (routine, clinically validated but non-routine, or investigational), incorporates the move of PD-1 blockade into first-line therapy (SWOG S1826) and the BrECADD regimen (HD21), proposes a minimum dataset for an integrated precision immunopathology report, and discusses the practical barriers—tissue availability, cost, turnaround time, standardization, and regulatory validation—that must be overcome before an ecosystem-centered diagnostic model can be translated into routine hematopathology practice.
- Open Access
Hodgkin Reed-Sternberg Cells of Classic Hodgkin Lymphoma: Morphology, Phenotype, Genotype, and Cell of Origin
Classic Hodgkin lymphoma (cHL) is a distinctive B-cell malignancy defined by the presence of scarce but pathobiologically dominant Hodgkin Reed-Sternberg (HRS) cells within an inflammatory tumor microenvironment (TME). Although representing less than 10% of total tumor cellularity, HRS cells shape the TME by recruiting and functionally polarizing immune and stromal elements through cytokine- and chemokine-mediated signaling. Morphologically, HRS cells are large, atypical, often binucleated or multinucleated cells with prominent eosinophilic nucleoli and abundant cytoplasm, giving rise to the classic “owl’s eye” appearance. Distinct morphological variants—including lacunar, mummified, mononuclear, and anaplastic forms—contribute to the histopathologic diversity across cHL subtypes such as nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted disease. The immunophenotype of HRS cells is equally characteristic, with strong and uniform CD30 expression, frequent CD15 positivity, reduced expression of B-cell markers (CD20, CD79A/B), and partial retention of PAX5, reflecting profound lineage dysregulation. Aberrant expression of activation markers and immune-evasion molecules, including PD-L1 driven by recurrent 9p24.1 amplification, underscores their capacity for immune escape. Genetically, HRS cells display alterations affecting NF-κB, JAK/STAT, and PI3K/AKT pathways, facilitated by somatic mutations, chromosomal gains, and epigenetic remodeling that silence B-cell-defining genes. Despite reprogramming, clonality and somatic hypermutation patterns confirm their origin from germinal center B-cells, even in EBV-associated cases. Collectively, the morphology, phenotype, and genotype of HRS cells reveal a complex pathogenic network in which intrinsic oncogenic pathways and extrinsic TME interactions co-operate to sustain malignant transformation. Understanding these integrated mechanisms provides a biological foundation for current therapeutic strategies.
Open AccessHodgkin Reed-Sternberg Cells of Classic Hodgkin Lymphoma: Morphology, Phenotype, Genotype, and Cell of Origin
Classic Hodgkin lymphoma (cHL) is a distinctive B-cell malignancy defined by the presence of scarce but pathobiologically dominant Hodgkin Reed-Sternberg (HRS) cells within an inflammatory tumor microenvironment (TME). Although representing less than 10% of total tumor cellularity, HRS cells shape the TME by recruiting and functionally polarizing immune and stromal elements through cytokine- and chemokine-mediated signaling. Morphologically, HRS cells are large, atypical, often binucleated or multinucleated cells with prominent eosinophilic nucleoli and abundant cytoplasm, giving rise to the classic “owl’s eye” appearance. Distinct morphological variants—including lacunar, mummified, mononuclear, and anaplastic forms—contribute to the histopathologic diversity across cHL subtypes such as nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted disease. The immunophenotype of HRS cells is equally characteristic, with strong and uniform CD30 expression, frequent CD15 positivity, reduced expression of B-cell markers (CD20, CD79A/B), and partial retention of PAX5, reflecting profound lineage dysregulation. Aberrant expression of activation markers and immune-evasion molecules, including PD-L1 driven by recurrent 9p24.1 amplification, underscores their capacity for immune escape. Genetically, HRS cells display alterations affecting NF-κB, JAK/STAT, and PI3K/AKT pathways, facilitated by somatic mutations, chromosomal gains, and epigenetic remodeling that silence B-cell-defining genes. Despite reprogramming, clonality and somatic hypermutation patterns confirm their origin from germinal center B-cells, even in EBV-associated cases. Collectively, the morphology, phenotype, and genotype of HRS cells reveal a complex pathogenic network in which intrinsic oncogenic pathways and extrinsic TME interactions co-operate to sustain malignant transformation. Understanding these integrated mechanisms provides a biological foundation for current therapeutic strategies.
- 19 March 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (6) , e70250
Transcriptomic Analysis of Children/Adolescents and Young Adults Versus Adult Synovial Sarcomas Reveals Age‐Related Molecular Features
Background: Synovial sarcoma (SS) is a rare malignancy, accounting for 5%–10% of all soft tissue sarcomas, and characterized by the SS18::SSX translocation. SS predominantly affects young individuals, with a peak incidence in the fourth decade of life. Children (29 years), with the aim of identifying age‐related molecular features of SS. In addition, enrichment of recently described transcriptional signatures associated with SS tumor components and infiltrating cell populations was evaluated in our dataset. Results: RNA‐seq analysis identified differential expression of RPL39 and GATA3 between children/AYA and adult patients. Immunohistochemical analysis confirmed increased GATA3 expression in adult tumors. Comparative analyses based on SS‐related transcriptional signatures further demonstrated enrichment of actively cycling tumor cells in adult samples, as well as a trend toward increased M2 macrophage infiltration in approximately half of the children/AYA samples. Conclusions: This study reveals age‐related molecular and tumor microenvironment differences in SS that may contribute to disparities in clinical outcomes. These findings underscore the need for further studies to validate these results and to support the development of age‐tailored therapeutic strategies.
- 19 March 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (6) , e70250
Transcriptomic Analysis of Children/Adolescents and Young Adults Versus Adult Synovial Sarcomas Reveals Age‐Related Molecular Features
Background: Synovial sarcoma (SS) is a rare malignancy, accounting for 5%–10% of all soft tissue sarcomas, and characterized by the SS18::SSX translocation. SS predominantly affects young individuals, with a peak incidence in the fourth decade of life. Children (29 years), with the aim of identifying age‐related molecular features of SS. In addition, enrichment of recently described transcriptional signatures associated with SS tumor components and infiltrating cell populations was evaluated in our dataset. Results: RNA‐seq analysis identified differential expression of RPL39 and GATA3 between children/AYA and adult patients. Immunohistochemical analysis confirmed increased GATA3 expression in adult tumors. Comparative analyses based on SS‐related transcriptional signatures further demonstrated enrichment of actively cycling tumor cells in adult samples, as well as a trend toward increased M2 macrophage infiltration in approximately half of the children/AYA samples. Conclusions: This study reveals age‐related molecular and tumor microenvironment differences in SS that may contribute to disparities in clinical outcomes. These findings underscore the need for further studies to validate these results and to support the development of age‐tailored therapeutic strategies.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Consistent Trophoblast Cell Surface Antigen 2 Positivity in Tracheobronchial Adenoid Cystic Carcinoma: Expanding Antibody-Drug Conjugate Opportunities in Rare Thoracic Tumor
PURPOSE: Tracheobronchial adenoid cystic carcinoma (TACC) is a rare malignancy arising from the submucosal glands of the trachea or main bronchi. Similar to its more common salivary gland counterpart (SG-ACC), TACCs display a strong propensity for local recurrence and distant metastases and current systemic treatment options are limited and often ineffective. Trophoblast cell surface antigen 2 (TROP-2) has emerged as a validated therapeutic target for antibody-drug conjugates (ADCs) and is highly expressed in SG-ACC. MATERIALS AND METHODS: We retrospectively analyzed 11 TACC specimens from the pathology archives of two Italian cancer reference centers. TROP-2 expression was assessed in all cases using immunohistochemistry. RESULTS: Immunohistochemistry for TROP-2 revealed positivity in all 11 specimens, with 10 showing high expression and one showing moderate expression. Three cases exhibited heterogeneous staining. CONCLUSION: These findings indicate a very high prevalence of robust TROP-2 expression in TACC. This provides a compelling rationale for the investigation of anti–TROP-2 ADCs, addressing a critical unmet need in this challenging rare thoracic malignancy.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Consistent Trophoblast Cell Surface Antigen 2 Positivity in Tracheobronchial Adenoid Cystic Carcinoma: Expanding Antibody-Drug Conjugate Opportunities in Rare Thoracic Tumor
PURPOSE: Tracheobronchial adenoid cystic carcinoma (TACC) is a rare malignancy arising from the submucosal glands of the trachea or main bronchi. Similar to its more common salivary gland counterpart (SG-ACC), TACCs display a strong propensity for local recurrence and distant metastases and current systemic treatment options are limited and often ineffective. Trophoblast cell surface antigen 2 (TROP-2) has emerged as a validated therapeutic target for antibody-drug conjugates (ADCs) and is highly expressed in SG-ACC. MATERIALS AND METHODS: We retrospectively analyzed 11 TACC specimens from the pathology archives of two Italian cancer reference centers. TROP-2 expression was assessed in all cases using immunohistochemistry. RESULTS: Immunohistochemistry for TROP-2 revealed positivity in all 11 specimens, with 10 showing high expression and one showing moderate expression. Three cases exhibited heterogeneous staining. CONCLUSION: These findings indicate a very high prevalence of robust TROP-2 expression in TACC. This provides a compelling rationale for the investigation of anti–TROP-2 ADCs, addressing a critical unmet need in this challenging rare thoracic malignancy.
- 8 July 2025
- Published by SAGE Publications in Tumori Journal
Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization
Introduction: Anti-HER2 drugs are becoming an important therapeutic option for various solid tumors, increasing the need for HER2 status testing. Comprehensive genomic profiling (CGP) panels, including FoundationOne®CDx, are commonly used to assess ERBB2 (encoding for HER2) copy number alterations. We aimed to evaluate the analytical validity of FoundationOne®CDx assay, by comparing ERBB2 copy number data with traditional HER2 status by immunohistochemistry (IHC)/in situ hybridization (ISH) assays in a heterogeneous cohort of solid tumor samples. Methods: We retrospectively reviewed the 531 cases evaluated by FoundationOne®CDx in our Institution, and HER2 status by IHC/ISH could be internally analyzed in 68 cases, including 31 (45.5%) gastroesophageal, 17 (25.0%) colorectal, four (5.8%) breast and two (2.9%) cholangiocarcinoma patients. Tumors with estimated ERBB2 copy number ⩾ 4 by FoundationOne®CDx, and tumors with strong and complete (3+) membranous staining by IHC and/or a HER2/CEP17 ratio ⩾2 by ISH were considered NGS positive and IHC/ISH positive, respectively. Results: We identified 21 NGS positive cases (30.9%); IHC/ISH analysis confirming overexpression/amplification in 16 cases (sensitivity: 76.2%), while among the 47 NGS negative cases, 45 were confirmed by IHC/ISH results (specificity: 90%), with a positive predictive value of 76.2% and a negative predictive value of 95.7%. Conclusions: FoundationOne®CDx provides an accurate evaluation of ERBB2 copy number status and may represent a cost-effective option in metastatic cancer patients for whom NGS testing is recommended.
- 8 July 2025
- Published by SAGE Publications in Tumori Journal
Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridization
Introduction: Anti-HER2 drugs are becoming an important therapeutic option for various solid tumors, increasing the need for HER2 status testing. Comprehensive genomic profiling (CGP) panels, including FoundationOne®CDx, are commonly used to assess ERBB2 (encoding for HER2) copy number alterations. We aimed to evaluate the analytical validity of FoundationOne®CDx assay, by comparing ERBB2 copy number data with traditional HER2 status by immunohistochemistry (IHC)/in situ hybridization (ISH) assays in a heterogeneous cohort of solid tumor samples. Methods: We retrospectively reviewed the 531 cases evaluated by FoundationOne®CDx in our Institution, and HER2 status by IHC/ISH could be internally analyzed in 68 cases, including 31 (45.5%) gastroesophageal, 17 (25.0%) colorectal, four (5.8%) breast and two (2.9%) cholangiocarcinoma patients. Tumors with estimated ERBB2 copy number ⩾ 4 by FoundationOne®CDx, and tumors with strong and complete (3+) membranous staining by IHC and/or a HER2/CEP17 ratio ⩾2 by ISH were considered NGS positive and IHC/ISH positive, respectively. Results: We identified 21 NGS positive cases (30.9%); IHC/ISH analysis confirming overexpression/amplification in 16 cases (sensitivity: 76.2%), while among the 47 NGS negative cases, 45 were confirmed by IHC/ISH results (specificity: 90%), with a positive predictive value of 76.2% and a negative predictive value of 95.7%. Conclusions: FoundationOne®CDx provides an accurate evaluation of ERBB2 copy number status and may represent a cost-effective option in metastatic cancer patients for whom NGS testing is recommended.
- 14 August 2023
- Published by SAGE Publications in Tumori Journal
- Vol. 110 (1) , 49-59
Periprosthetic effusions surrounding breast expander: a flow cytometric, immunohistochemical and molecular characterization
Introduction: The synthesis of the periprosthetic capsule during implant-based breast reconstruction is the result of a coordinate cascade of inflammatory events ending in a fibrous tissue deposition around the expander or implant. Although the development of small volumes of fluid is one of the complications of prosthetic-based breast reconstruction, the characterization of the periprosthetic effusions coupled with the micro-textured devices, that have been recently introduced after the recall of macro-textured ones, is still lacking. The investigation of these periprosthetic effusions and paired capsules in terms of immunological content were the primary and secondary aims of the present study, respectively. Methods: For this, 68 women, 41 of whom had periprosthetic effusions at the time of expander replacement with implant, were recruited. For each case, capsule and healthy dermal tissues were taken and for women with periprosthetic effusion, peripheral blood was also collected. Periprosthetic effusions and peripheral blood were characterized by cytometry while capsules and dermal tissues by immunohistochemistry and Nanostring analysis. Results: The results showed an increase of Th1, Th2 lymphocytes and a HLA-DR+bright CD16+ cells (likely representing monocytes-derived macrophages) in periprosthetic effusions in respect to peripheral blood. These pro-inflammatory cells were counterbalanced by the gain of suppressive CD4 Treg cells. In the corresponding capsules, immunohistochemistry revealed the absence of Th1 cells and the presence of tissutal FOXP3 Treg. No significant difference in expression of inflammatory-related genes between capsules and dermal tissues was present. Conclusions: These results suggest the presence of a Treg-controlled inflammation in both periprosthetic effusions and capsules.
- 14 August 2023
- Published by SAGE Publications in Tumori Journal
- Vol. 110 (1) , 49-59
Periprosthetic effusions surrounding breast expander: a flow cytometric, immunohistochemical and molecular characterization
Introduction: The synthesis of the periprosthetic capsule during implant-based breast reconstruction is the result of a coordinate cascade of inflammatory events ending in a fibrous tissue deposition around the expander or implant. Although the development of small volumes of fluid is one of the complications of prosthetic-based breast reconstruction, the characterization of the periprosthetic effusions coupled with the micro-textured devices, that have been recently introduced after the recall of macro-textured ones, is still lacking. The investigation of these periprosthetic effusions and paired capsules in terms of immunological content were the primary and secondary aims of the present study, respectively. Methods: For this, 68 women, 41 of whom had periprosthetic effusions at the time of expander replacement with implant, were recruited. For each case, capsule and healthy dermal tissues were taken and for women with periprosthetic effusion, peripheral blood was also collected. Periprosthetic effusions and peripheral blood were characterized by cytometry while capsules and dermal tissues by immunohistochemistry and Nanostring analysis. Results: The results showed an increase of Th1, Th2 lymphocytes and a HLA-DR+bright CD16+ cells (likely representing monocytes-derived macrophages) in periprosthetic effusions in respect to peripheral blood. These pro-inflammatory cells were counterbalanced by the gain of suppressive CD4 Treg cells. In the corresponding capsules, immunohistochemistry revealed the absence of Th1 cells and the presence of tissutal FOXP3 Treg. No significant difference in expression of inflammatory-related genes between capsules and dermal tissues was present. Conclusions: These results suggest the presence of a Treg-controlled inflammation in both periprosthetic effusions and capsules.
- Open Access
- 20 July 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (7) , 2049
A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei
In pseudomyxoma peritonei (PMP), KRAS and GNAS mutations are frequent. We hypothesized that these mutations may contribute to the suppression of antitumor immunity: KRAS may induce GMCSF expression, while GNAS may enhance the expression of cyclic adenosine monophosphate and A2AR signaling. This study aimed to explore possible mechanisms facilitated by KRAS and GNAS mutations for escaping immune surveillance. Additionally, we looked for new potential therapeutic and prognostic targets in this rare disease which is poorly characterized at the molecular level. GM-CSF, A2AR, CD73, CD39, and PD-L1 expression was investigated by immunohistochemistry in 40 PMPs characterized for GNAS and KRAS mutational status. Immune cell populations were studied by immunohistochemistry and nanostring nCounter®. Following the criteria of a prognostic nomogram reported for PMP, we stratified the patients into two different risk groups, with 28 “low-risk” and 12 “high-risk” patients. We observed the expression of GM-CSF (74%); CD39 (37%); CD73 (53%); A2AR (74%); and PD-L1 (16%) which was unrelated to GNAS or KRAS status. The tumor microenvironment showed the presence of CD4+ T cells (86%); CD8+ T cells (27%); CD20+ B (67%); CD15+ cells (86%); and CD163+ M2 macrophages (67%), while CD56+ NK cells were absent. CD163 expression (27%) in PMP tumor cells was associated with poor prognosis. GNAS mutation and A2AR expression were not associated with a specific immune transcriptional signature. However, the expression assay revealed 21 genes associated with prognosis. The “high-risk” patients exhibited worse progression-free survival (HR = 2.3, CI 95%: 1.1–5.1, p = 0.034) and significant downregulation of MET, IL8, PPARG, DTX4, HMGA1, ZIC2, WNT5B, and CCRL2. In conclusion, we documented the presence of immunosuppressive factors such as GM-CSF, A2AR, and PD-L1 in PMP. These factors were not associated with GNAS and KRAS status and could be explored as therapeutic molecular targets. Additionally, a set of potential prognostic biomarkers, including CD163 expression in tumor cells, deserve further investigation.
- 20 July 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (7) , 2049
Open AccessA2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei
In pseudomyxoma peritonei (PMP), KRAS and GNAS mutations are frequent. We hypothesized that these mutations may contribute to the suppression of antitumor immunity: KRAS may induce GMCSF expression, while GNAS may enhance the expression of cyclic adenosine monophosphate and A2AR signaling. This study aimed to explore possible mechanisms facilitated by KRAS and GNAS mutations for escaping immune surveillance. Additionally, we looked for new potential therapeutic and prognostic targets in this rare disease which is poorly characterized at the molecular level. GM-CSF, A2AR, CD73, CD39, and PD-L1 expression was investigated by immunohistochemistry in 40 PMPs characterized for GNAS and KRAS mutational status. Immune cell populations were studied by immunohistochemistry and nanostring nCounter®. Following the criteria of a prognostic nomogram reported for PMP, we stratified the patients into two different risk groups, with 28 “low-risk” and 12 “high-risk” patients. We observed the expression of GM-CSF (74%); CD39 (37%); CD73 (53%); A2AR (74%); and PD-L1 (16%) which was unrelated to GNAS or KRAS status. The tumor microenvironment showed the presence of CD4+ T cells (86%); CD8+ T cells (27%); CD20+ B (67%); CD15+ cells (86%); and CD163+ M2 macrophages (67%), while CD56+ NK cells were absent. CD163 expression (27%) in PMP tumor cells was associated with poor prognosis. GNAS mutation and A2AR expression were not associated with a specific immune transcriptional signature. However, the expression assay revealed 21 genes associated with prognosis. The “high-risk” patients exhibited worse progression-free survival (HR = 2.3, CI 95%: 1.1–5.1, p = 0.034) and significant downregulation of MET, IL8, PPARG, DTX4, HMGA1, ZIC2, WNT5B, and CCRL2. In conclusion, we documented the presence of immunosuppressive factors such as GM-CSF, A2AR, and PD-L1 in PMP. These factors were not associated with GNAS and KRAS status and could be explored as therapeutic molecular targets. Additionally, a set of potential prognostic biomarkers, including CD163 expression in tumor cells, deserve further investigation.